Moderna is at the forefront of mRNA technology, focusing on the development of mRNA medicines that leverage the body's natural processes to combat diseases. Messenger RNA (mRNA) serves as a critical component in this innovative approach, as it carries genetic instructions that direct cells to produce proteins essential for fighting diseases. This technology allows for the rapid design and testing of various mRNA constructs, enabling Moderna to create vaccines and therapeutics more efficiently than traditional methods. The company emphasizes the versatility of mRNA, believing it can be applied to a wide range of diseases, including those currently lacking effective treatments.

The mRNA pipeline at Moderna showcases a diverse array of clinical programs aimed at addressing various health challenges, including infectious diseases, cancer, and rare genetic disorders. With multiple vaccines in advanced stages of development, such as those for COVID-19 and influenza, Moderna is committed to making its medicines accessible and effective. The company also invests in ongoing research through initiatives like New Venture Labs, which explores new applications for mRNA technology beyond its current uses. This commitment to innovation positions Moderna as a leader in the evolving landscape of biotechnology, with the potential to transform how diseases are treated and prevented.

United States

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. 

Cancer

Infectious Diseases

Skin Diseases

Moderna

COVID-19

mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by&nbsp;Moderna&nbsp;in collaboration with investigators from&nbsp;Vaccine Research Center&nbsp;(VRC) at the&nbsp;National Institute of Allergy and Infectious Diseases&nbsp;(NIAID), a part of the&nbsp;NIH.

mRNA-1273 

Spikevax®

Next-generation vaccine candidate against COVID-19 (mRNA-1283): The Phase 1 study of mRNA-1283 is fully enrolled and ongoing. An interim analysis of data from the Phase 1 study of mRNA-1283 at three dose levels indicate that a lower dose of mRNA-1283 achieved similar neutralizing antibody responses compared to a primary series of mRNA-1273. mRNA-1283 had an acceptable tolerability profile. The Company expects to start a Phase 2 booster study in the near term. mRNA-1283 is a next-generation vaccine candidate against COVID-19 that encodes for the portions of the SARS-CoV-2 spike protein critical for neutralization, specifically the Receptor Binding Domain (RBD) and N-terminal Domain (NTD). The encoded mRNA-1283 antigen is shorter than mRNA-1273 and is being developed as a potential refrigerator-stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers.

mRNA-1283

Respiratory syncytial virus

mRNA-1345 is an investigational RSV vaccine that consists of a single mRNA sequence encoding for a stabilized prefusion F glycoprotein. The vaccine uses the same lipid nanoparticles (LNPs) as in the Moderna COVID-19 vaccines. The F glycoprotein is on the surface of the virus and is required for infection by helping the virus to enter host cells. It exists in two states, prefusion and postfusion. The prefusion conformation is a significant target of potent neutralizing antibodies, and the protein sequences are largely similar across both RSV-A and RSV-B subtypes.

mRESVIA (mRNA-1345)

Influenza

mRNA-1010 is a quadrivalent seasonal influenza vaccine candidate targeting WHO recommendations including A H1N1, H3N2 and influenza B Yamagata and Victoria lineages

mRNA-1010 

mRNA-1083

Melanoma

mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient's tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity

mRNA-4157/V940 +KEYTRUDA

Cytomegalovirus

mRNA-1647

Methylmalonic acidemia

Rare diseases

MMA therapy candidate,mRNA-3705 encodes for a missing or deficient hepatic enzyme.

mRNA-3705

Non-small cell lung carcinoma

mRNA-4157/V940 +KEYTRUDA 

Gastroenteritis

Norovirus

mRNA-1403 is an mRNA vaccine in development to prevent moderate to severe acute gastroenteritis caused by norovirus. The vaccine candidate is a trivalent formulation containing mRNA that encodes for virus-like particles (VLPs) designed to protect against multiple norovirus genotypes.

mRNA-1403

Human immunodeficiency virus

mRNA-1574

Varicella-zoster virus

mRNA-1468

Propionic acidemia

mRNA-3927 is a novel, IV-administered, lipid nanoparticle (LNP)-encapsulated dual investigational mRNA therapy that encodes for PCCA and PCCB subunit proteins to restore functional PCC enzyme activity in the liver. By encoding for the PCC enzyme, mRNA-3927 has the potential to replace a missing or dysfunctional enzyme.

Moderna

Company Details